Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.

Abstract

OBJECTIVE Docetaxel (DTX) remains the only effective drug for prolonging survival and improving quality of life of metastatic castration-resistant prostate cancer (mCRPC) patients. Combination anticancer therapy encapsulating DTX and another extract of traditional Chinese medicine is one nano-sized drug delivery system promising to generate synergistic… (More)
DOI: 10.3109/10717544.2015.1069423

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Statistics

010020020162017
Citations per Year

Citation Velocity: 45

Averaging 45 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.

Slides referencing similar topics